Abstract
Osteoclast stimulatory transmembrane protein (OC-STAMP) plays a pivotal role in the promotion of cell fusion during osteoclast differentiation (osteoclastogenesis) in the context of pathogenic bone resorption. Thus, it is plausible that the suppression of OC-STAMP through a bioengineering approach could lead to the development of an effective treatment for inflammatory bone resorptive diseases with minimum side effects. Here, we synthesized two types of spermine-bearing (Spe) cationic glucan dendrimer (GD) gels (with or without C12) as carriers of short interfering RNA (siRNA) to silence OC-STAMP. The results showed that amphiphilic C12-GD-Spe gel was more efficient in silencing OC-STAMP than GD-Spe gel and that the mixture of anti-OC-STAMP siRNA/C12-GD-Spe significantly downregulated RANKL-induced osteoclastogenesis. Also, local injection of anti-OC-STAMP-siRNA/C12-GD-Spe could attenuate bone resorption induced in a mouse model of periodontitis. These results suggest that OC-STAMP is a promising target for the development of a novel bone regenerative therapy and that C12-GD-Spe gel provides a new nanocarrier platform of gene therapies for osteolytic disease.
| Original language | English |
|---|---|
| Journal | Gels |
| Volume | 10 |
| Issue number | 6 |
| DOIs | |
| State | Published - May 31 2024 |
Funding
This study was founded by an Osteology Foundation grant (#16-195) and, in part, supported by NIH grants (DE027851, DE028715, and DE029709) and by grants-in-aid from JSPS (19K24075 and 21K09937).
Keywords
- OC-STAMP
- cationic glycan dendrimer
- drug delivery systems
- regenerative medicine
- siRNA
Disciplines
- Pharmacy and Pharmaceutical Sciences